Selank: Comprehensive Research Guide

1. Introduction

Selank (international nonproprietary designation: TP-7; CAS 129954-34-3) is a synthetic heptapeptide first developed at the Institute of Molecular Genetics of the Russian Academy of Sciences (IMG RAS) in the late 1980s under the direction of Professor Igor Petrovich Ashmarin. The compound was constructed by appending a Pro-Gly-Pro (glyproline) tripeptide to the C-terminus of tuftsin, the endogenous immunomodulatory tetrapeptide Thr-Lys-Pro-Arg that is cleaved from the Fc region of immunoglobulin G heavy chains. The resulting heptapeptide sequence—Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP)—carries a molecular formula of C₃₃H₅₇N₁₁O₉ and an average molecular weight of approximately 751.87 g/mol.

The central design goal of this molecular engineering was twofold: first, to confer metabolic stability on the parent tuftsin scaffold, which is rapidly degraded in plasma by aminopeptidases and carboxypeptidases; second, to extend the pharmacological spectrum beyond tuftsin’s primarily immunological activity into the central nervous system, exploiting the intrinsic neuropeptide properties of the Pro-Gly-Pro motif. Both objectives were achieved. Selank demonstrates exceptional intranasal bioavailability (92.8%), rapid CNS penetration, and a prolonged pharmacodynamic duration (20–24 hours) that is mechanistically decoupled from its comparatively short plasma half-life.

The compound’s most clinically significant feature—confirmed in Russian-language randomized clinical trials and corroborated by extensive preclinical mechanistic studies—is its ability to produce anxiolytic effects equivalent to classical benzodiazepines such as medazepam and phenazepam, while producing none of the sedation, cognitive impairment, motor dysfunction, tolerance, or physical dependence that limit long-term benzodiazepine use. This profile emerges from a pleiotropic mechanism that modulates GABA-A receptors indirectly, inhibits enkephalin-degrading enzymes, normalizes monoaminergic neurotransmitter systems, upregulates brain-derived neurotrophic factor (BDNF) in the hippocampus, and regulates Th1/Th2 cytokine balance. Selank received regulatory approval in the Russian Federation for generalized anxiety disorder (GAD) and neurasthenia in 2009. Outside Russia and select CIS countries, it carries research chemical status only.

This review synthesizes the published preclinical and clinical evidence for Selank, with emphasis on its mechanism of action, key studies, comparative pharmacology, regulatory landscape, and research-grade handling protocols. All content is prepared for scientific research purposes only and is not intended to promote or guide human therapeutic use.

2. Mechanism of Action

Selank’s pharmacological profile is multi-modal, involving simultaneous engagement of at least four major molecular systems: the GABAergic system, the enkephalin/endogenous opioid system, monoaminergic neurotransmitter pathways, and the neurotrophin/neuroimmune axis. This pleiotropic mechanism distinguishes Selank from single-target anxiolytics and provides the mechanistic basis for its unique combination of anxiolysis, preserved cognition, and immune modulation.

2.1 GABAergic Modulation

Gamma-aminobutyric acid (GABA) is the principal inhibitory neurotransmitter of the CNS, and the GABA-A receptor is the primary molecular target of classical benzodiazepine anxiolytics. Benzodiazepines function as direct positive allosteric modulators at the benzodiazepine-binding site (located at the α–γ subunit interface of the GABA-A heteropentamer), increasing the frequency of chloride channel opening and globally suppressing neuronal excitability. This indiscriminate inhibitory enhancement underlies their efficacy but also their side-effect burden—sedation, cognitive impairment, muscle relaxation, tolerance, and dependence.

Selank engages the GABAergic system through a fundamentally different route. V’yunova et al. (2014) demonstrated that Selank alters the number of specific binding sites for [²H]-GABA without affecting receptor affinity, indicating it modifies the conformational equilibrium of the GABA-A receptor complex by binding to a separate peptide receptor site—an indirect allosteric mechanism rather than direct channel activation. Four lines of evidence converge on this model:

• Binding data: Intranasal pre-administration of Selank changes [²H]-GABA binding without displacing classical benzodiazepine ligands, consistent with a distinct allosteric site.
• Gene expression correlation: Volkova et al. (2016) showed that at 1 hour post-administration, the frontal cortex mRNA changes induced by Selank (300 µg/kg intranasal) correlated strongly with those produced by equidose GABA (r = 0.86, p ≤ 0.05) across 45 of 77 analyzable neurotransmission genes—supporting common downstream GABAergic signaling despite mechanistically different upstream actions.
• Diazepam potentiation: Kasian et al. (2017) demonstrated that in rats under unpredictable chronic mild stress (UCMS), the combination of Selank + diazepam produced greater anxiolysis than either drug alone, with anxiety scores returning to pre-stress baseline—consistent with Selank acting as a positive modulator of benzodiazepine affinity at GABA-A.
• Cell line evidence: Alieva et al. (2017) found that in IMR-32 neuroblastoma cells (which express functional GABA-A receptors), Selank alone did not significantly change GABAergic gene expression, while GABA + Selank nearly completely suppressed the gene changes that GABA induced alone—confirming that Selank modulates GABA’s receptor interaction rather than acting as a direct agonist.

A particularly important gene expression finding is the dynamic behavior of Hcrt (hypocretin/orexin precursor). Volkova et al. (2016) observed an initial 25-fold decrease in Hcrt mRNA at 1 hour, followed by a 128-fold increase at 3 hours after Selank administration. This orexin surge at the 3-hour time point mechanistically accounts for Selank’s failure to produce sedation: orexin/hypocretin neurons are primary drivers of wakefulness, and their robust activation after the initial inhibitory phase effectively counteracts any sedative tendency arising from GABAergic modulation. This mechanism is absent with classical benzodiazepines, which suppress orexin signaling.

2.2 Enkephalinase Inhibition

Enkephalins (leucine-enkephalin, methionine-enkephalin) are endogenous opioid pentapeptides that bind μ- and δ-opioid receptors to modulate pain, mood, and stress response. They are rapidly inactivated in plasma and CNS by zinc metallopeptidases collectively termed enkephalinases, including neprilysin (NEP), aminopeptidase N, and dipeptidylaminopeptidase.

Zozulya et al. (2001) established a key pathophysiological connection: patients with generalized anxiety disorder (GAD)—but not those with panic disorder or agoraphobia—demonstrated significantly shortened enkephalin half-life (τ½ leu-enkephalin) and reduced total enkephalinase activity in peripheral blood. This enkephalinase hyperactivity in GAD implies that accelerated enkephalin degradation may represent a disorder-specific biological substrate, reducing the endogenous anxiolytic opioid tone.

In the same study, Selank dose-dependently inhibited enzymatic hydrolysis of plasma enkephalin with an IC₅₀ of 15 µM—exceeding the inhibitory potency of classical peptidase inhibitors bacitracin and puromycin. The proposed mechanism involves competitive occupancy at the enkephalinase active site or exosite by Selank’s proline-rich C-terminus (Arg-Pro-Gly-Pro), which slows substrate turnover without directly activating opioid receptors. By preserving endogenous enkephalin from premature degradation, Selank augments the endogenous opioid anxiolytic tone through a mechanism independent of, and complementary to, its GABAergic actions.

Clinical confirmation came from the landmark 2008 GAD trial (Zozulya, Neznamov et al., 2008, n=62): patients receiving Selank for 14 days showed progressive increases in τ½ leu-enkephalin that correlated positively with reductions in anxiety severity on the Hamilton Anxiety Rating Scale (HAM-A). Patients receiving medazepam did not show this enkephalin-restoring effect, highlighting an independent mechanistic pathway unique to Selank among anxiolytics.

2.3 Serotonin, Norepinephrine, and Dopamine

Selank modulates all three major monoamine neurotransmitter systems, providing the neurochemical basis for its antiasthenic, psychostimulant, and nootropic properties.

Serotonin: Semenova et al. (2007) demonstrated that Selank compensated for hypoxia-induced serotonin depletion in adult rats, producing a 111% increase in serotonin levels in the neocortex and a 30% increase in the brainstem of hypoxia-exposed animals. At the gene expression level, Volkova et al. (2016) identified selective upregulation of Htr1b (5-HT1B receptor) and Htr3a (5-HT3A receptor) at the 3-hour time point—changes unique to Selank and not replicated by GABA administration. These serotonergic effects provide a mechanistic foundation for Selank’s documented antidepressant and anti-stress activity.

Dopamine: Selank exerts distinctive dopaminergic effects through receptor gene upregulation rather than direct monoamine release. At 1 hour, Selank selectively increases mRNA levels of Drd1a (D1 receptor) and Drd2 (D2 receptor). By 3 hours, Drd5 (D5 receptor) is uniquely elevated. The D5 receptor is expressed prominently in the hippocampus and prefrontal cortex, where it couples to adenylate cyclase to facilitate long-term potentiation (LTP)—providing a direct molecular substrate for the memory consolidation and cognitive enhancement effects observed in both preclinical models and clinical observations.

Norepinephrine: Selank normalizes norepinephrine concentrations in the hypothalamus and neocortex. Narkevich et al. (2008) demonstrated strain-dependent effects on dopamine metabolites and norepinephrine in BALB/c and C57BL/6 mice, while Semenova et al. (2007) showed that Selank reversed hypoxia-induced noradrenaline depletion. The elevation of norepinephrine tone in prefrontal and limbic circuits underlies the psychostimulant and antiasthenic effects that distinguish Selank from purely inhibitory anxiolytics and that were documented clinically in the Zozulya et al. (2008) trial.

2.4 BDNF Modulation and Neuroprotection

Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family that is critical for neuronal survival, synaptic plasticity, hippocampal neurogenesis, and memory consolidation. Reduced BDNF expression is associated with depression, anxiety disorders, and neurodegenerative conditions.

Inozemtseva et al. (2008) demonstrated that a single intranasal administration of Selank rapidly elevated BDNF mRNA expression in the rat hippocampus, establishing a rapid neurotrophic response as part of Selank’s early pharmacodynamic profile. Critically, Kolik et al. (2019) later clarified that Selank’s BDNF-related neuroprotection involves normalization rather than indiscriminate upregulation: in rats with ethanol-induced increases in hippocampal and prefrontal cortex BDNF content, Selank (0.3 mg/kg × 7 days) returned BDNF levels toward physiological baseline (p < 0.05) while simultaneously preventing the formation of withdrawal-associated memory and attention disturbances (p < 0.01 in the object recognition test). This homeostatic regulation of neurotrophin signaling—rather than simple BDNF augmentation—likely represents the mature neuroprotective mechanism, buffering against both neurotrophin deficiency and excess.

2.5 Immune System Interactions

Selank’s immunomodulatory profile is a direct inheritance from its tuftsin ancestry, amplified and diversified by the Pro-Gly-Pro extension. Tuftsin (Thr-Lys-Pro-Arg) is an endogenous phagocytosis-stimulating tetrapeptide that directs macrophage and neutrophil activity. Selank inherits this immune-activating scaffold while adding additional immunoregulatory dimensions.

Kolomin et al. (2010–2014) demonstrated that Selank controls the expression of 34 genes influencing inflammatory processes in mouse hippocampus and spleen, encoding cytokines, chemokines, and their receptors. Notably, Selank modulates Bcl6 expression—a transcription factor governing germinal center B-cell responses and T-helper cell differentiation. Uchakina et al. (2008) provided the clinical correlate: 14-day in vivo treatment normalized the Th1/Th2 cytokine imbalance in GAD/neurasthenia patients, with an inverse dynamic correlation between Th1 and Th2 cytokine markers over the treatment course.

At the cellular level, Uchakina et al. (2008) showed that Selank at 10⁻⁷ M completely suppressed IL-6 gene expression in peripheral blood leukocytes of depressed patients. Because elevated IL-6 directly impairs hippocampal neurogenesis, reduces BDNF expression, and dysregulates serotonin metabolism, this IL-6 suppression integrates the immune and neurological arms of Selank’s mechanism. Ershov et al. (2009) extended the antiviral dimension: prophylactic Selank completely suppressed influenza A/H3N2 replication in cell culture, while in vivo administration selectively induced IFN-α gene expression without activating pro-inflammatory TNF-α, IL-4, or IL-10—a pattern consistent with targeted Th1-biased innate immune priming without inflammatory excess.

3. Chemical Profile

Selank is a synthetic linear heptapeptide. Research-grade material is typically supplied as the diacetate salt in lyophilized (freeze-dried) powder form, with a target HPLC purity of ≥99.5% (main peak, 214 nm) for high-quality research applications. The primary chemical identifiers and physicochemical parameters are summarized in the table below.

3.1 Structural Features

Selank is a linear heptapeptide whose N-terminal tetrapeptide Thr-Lys-Pro-Arg corresponds exactly to tuftsin, the naturally occurring immunomodulatory tetrapeptide cleaved from the Fc-γ region of IgG heavy chains by tuftsin endocarboxypeptidase. Tuftsin was originally characterized by Naim et al. in 1974 and named after Tufts University. Selank was constructed by appending a Pro-Gly-Pro (glyproline) tripeptide to the tuftsin C-terminus, a rational design strategy pioneered at IMG RAS to simultaneously enhance metabolic stability and expand biological activity into the CNS.

Three proline residues at positions 3, 5, and 7 are structurally central to Selank’s character. Proline’s pyrrolidine ring introduces conformational rigidity, limits backbone flexibility, and reduces susceptibility to general proteolytic attack. The Pro-Gly-Pro C-terminal extension specifically shields the free C-terminus from carboxypeptidase-mediated hydrolysis. Primary biodegradation yields three metabolically active fragments: Thr-Lys-Pro, Arg-Pro, and Gly-Pro, each retaining a subset of the parent molecule’s biological activities. This “metabolite activity cascade” contributes to the extended pharmacodynamic duration that exceeds the plasma half-life of the intact peptide.

4. Key Research Studies

The following studies represent the most significant published investigations into Selank’s mechanism of action, clinical efficacy, and safety profile. All citations are provided in full with PubMed identifiers where available.

Study 1: Zozulya et al. (2001) — Enkephalinase Inhibition Mechanism

Citation: Zozulya AA, Kost NV, Sokolov OYu, Gabaeva MV, Grivennikov IA, Andreeva LN, et al. “The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity.” Bulletin of Experimental Biology and Medicine. 2001;131(4):315–317. doi: 10.1023/a:1017979514274. PMID: 11550013.

Design: Clinical observation (patients with anxiety disorders per DSM-IV: GAD, panic disorder, agoraphobia) combined with in vitro biochemical assay of enkephalinase inhibition.

Key findings:

• Patients with GAD showed significantly shortened enkephalin half-life and reduced total enkephalinase activity in peripheral blood versus panic disorder and agoraphobia patients
• Selank dose-dependently inhibited enzymatic hydrolysis of plasma enkephalin; IC₅₀ = 15 µM
• Selank exceeded bacitracin and puromycin in enkephalinase inhibitory potency

Significance: Established the enkephalinase inhibition mechanism and provided the first molecular link between GAD-specific pathophysiology (enkephalin deficiency) and Selank’s anxiolytic target.

Study 2: Zozulya, Neznamov et al. (2008) — Landmark GAD Clinical Trial

Citation: Zozulia AA, Neznamov GG, Siuniakov TS, Kost NV, Gabaeva MV, Sokolov OIu, et al. “[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia].” Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova. 2008;108(4):38–48. [In Russian]. PMID: 18454096.

Design: Randomized controlled clinical trial. N = 62 patients with GAD and neurasthenia per ICD-10 criteria. Selank arm: n = 30; medazepam (classical benzodiazepine) arm: n = 32. Assessment instruments: Hamilton Anxiety Rating Scale (HAM-A), Zung Self-Rating Anxiety Scale, Clinical Global Impression (CGI). Serum enkephalin activity measured at multiple time points.

Key findings:

• Anxiolytic effects of Selank were equivalent to medazepam across all psychometric instruments
• Selank produced additional antiasthenic and psychostimulant effects not observed in the medazepam arm, per CGI subscales
• GAD and neurasthenia patients demonstrated baseline reductions in τ½ leu-enkephalin correlated with disease duration, anxiety severity, asthenia, and autonomic dysfunction
• Selank treatment progressively restored enkephalin half-life; increases correlated positively with HAM-A score improvements, particularly in GAD patients
• Medazepam did not restore enkephalin half-life

Significance: The foundational human clinical trial for Selank. Directly informed the 2009 Russian Federation regulatory approval for GAD and neurasthenia.

Study 3: Uchakina et al. (2008) — Immunomodulatory Effects in Anxiety-Asthenic Disorders

Citation: Uchakina ON, Uchakin PN, Miasoedov NF, Andreeva LA, Shcherbenko VE, Mezentseva MV, et al. “[Immunomodulatory effects of selank in patients with anxiety-asthenic disorders].” Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova. 2008;108(5):71–75. [In Russian]. PMID: 18577961.

Design: Combined in vitro (peripheral blood of depressed patients) and in vivo (14-day treatment in GAD/neurasthenia patients) study.

Key findings:

• In vitro: Selank at 10⁻⁷ M completely suppressed IL-6 gene expression in peripheral blood leukocytes of depressed patients while increasing IL-6 protein concentration in cell culture—a concentration-dependent regulatory effect absent in healthy controls
• In vivo: 14-day treatment produced significant normalization of Th1/Th2 cytokine balance in serum of GAD/neurasthenia patients
• Immunomodulatory profile reflects normalization rather than global immune suppression

Significance: Established the neuroimmunological framework for Selank’s action, extending its pharmacological reach from neurological to immune domains and providing the rationale for subsequent antiviral investigations.

Study 4: Ershov, Uchakin et al. (2009) — Antiviral Activity Against Influenza

Citation: Ershov FI, Uchakin PN, Uchakina ON, Mezentseva MV, Alekseeva LA, Miasoedov NF. “[Antiviral activity of immunomodulator Selank in experimental influenza infection].” Voprosy Virusologii (Problems of Virology). 2009;54(5):19–24. [In Russian]. PMID: 19882898.

Design: In vitro and in vivo study against influenza virus strain A/Aichi 2/68 (H3N2).

Key findings:

• Selank added to cell culture 24 hours before viral inoculation completely suppressed viral reproduction
• In vivo prophylactic administration produced the highest animal survival rates
• Selank induced IFN-α gene expression selectively, without activating IL-4, IL-10, or TNF-α

Significance: Demonstrated genuine antiviral activity extending beyond anxiety-associated cytokine normalization, with a Th1-biased innate immune priming pattern that avoids inflammatory excess.

Study 5: Volkova et al. (2016) — GABAergic Gene Expression (Frontiers in Pharmacology)

Citation: Volkova A, Shadrina M, Kolomin T, Andreeva L, Limborska S, Myasoedov N, Slominsky P. “Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission.” Frontiers in Pharmacology. 2016;7:31. doi: 10.3389/fphar.2016.00031. PMID: 26924987. PMC: PMC4757669.

Design: Controlled preclinical study in male Wistar rats. Intranasal administration of Selank or GABA (300 µg/kg). Real-time PCR analysis of 84 neurotransmission genes in rat frontal cortex at 1-hour and 3-hour time points.

Key findings:

• At 1 hour: 45 of 77 analyzable genes showed significant mRNA changes; strong positive correlation with GABA-induced changes (r = 0.86, p ≤ 0.05)
• Most pronounced decreases at 1 hour: Gabre and Gabrq (20-fold reduction)
• Selank-unique at 1 hour: Drd1a, Drd2 (dopamine receptors), Ptgs2 (COX-2), Slc6a13 (GABA transporter GAT-2)
• At 3 hours: Hcrt (orexin precursor) increased 128-fold; Drd5 and serotonin receptor genes uniquely elevated

Significance: The most detailed mechanistic portrait of Selank’s genomic action to date, linking anxiolytic effects to allosteric GABAergic modulation while illuminating the dopaminergic and orexinergic contributions to its non-sedating, nootropic profile. Published in an international peer-reviewed journal with open-access availability.

Study 6: Kasian et al. (2017) — Selank-Diazepam Interaction in UCMS Model

Citation: Kasian A, Kolomin T, Andreeva L, Bondarenko E, Myasoedov N, Slominsky P, Shadrina M. “Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats.” Behavioural Neurology. 2017;2017:5091027. doi: 10.1155/2017/5091027. PMC: PMC5322660.

Design: Controlled rat study using unpredictable chronic mild stress (UCMS) model. Treatment groups: saline, Selank (300 µg/kg intranasal), diazepam (1 mg/kg oral), Selank + diazepam. Elevated plus maze (EPM) assessment. No-stress control group for baseline comparison.

Key findings:

• Without stress: Selank alone most effectively reduced elevated anxiety versus all other groups
• Under UCMS: Selank + diazepam combination nearly completely eliminated stress-induced anxiety; EPM scores did not differ from pre-stress baseline
• Combination increased time in open arms 8.9-fold versus saline under UCMS
• No tolerance observed after 14 days of Selank administration
• Combination did not increase diazepam-associated motor impairment

Significance: Demonstrates that Selank may enhance benzodiazepine anxiolysis at lower doses, potentially allowing benzodiazepine dose reduction without compromising efficacy. Published in an international peer-reviewed journal with open-access availability.

Study 7: Medvedev et al. (2014) — Comparison with Phenazepam

Citation: Medvedev VE, Tereshchenko ON, Israelian AYu, et al. “[A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders].” Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova. 2014;114(7):17–22. [In Russian]. PMID: 25176261.

Design: Comparative clinical study. N = 60 patients with phobic-anxiety and somatoform disorders (ICD-10 codes F40.2-9, F41.1-9, F45.0-1).

Key findings:

• Selank demonstrated pronounced anxiolytic and mild nootropic effects
• Anxiolytic effect persisted for one week following the last dose—an effect not observed with benzodiazepines, where rebound anxiety is characteristic
• Selank had a measurable positive impact on patient quality of life
• Overall tolerability was favorable with no serious adverse events

Significance: The durable post-treatment anxiolysis (one-week persistence) is consistent with epigenetic or gene expression changes underlying Selank’s mechanism, and distinguishes it from purely pharmacokinetic anxiolysis.

Study 8: Kolik et al. (2019) — BDNF and Memory Protection

Citation: Kolik LG, Nadorova AV, Antipova TA, Kruglov SV, Kudrin VS, Durnev AD. “Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats.” Bulletin of Experimental Biology and Medicine. 2019;167(5):641–644. doi: 10.1007/s10517-019-04588-9. PMID: 31625062.

Design: Controlled animal study. Outbred rats consuming 10% ethanol as sole fluid for 30 weeks. Selank 0.3 mg/kg/day × 7 days intraperitoneally. Object recognition test (ORT). BDNF quantification in hippocampus and prefrontal cortex.

Key findings:

• In non-ethanol-exposed 9-month-old rats, Selank produced a significant cognitive-stimulating effect in the ORT (p < 0.05)
• Selank prevented formation of ethanol-withdrawal-induced memory and attention disturbances (p < 0.01)
• Selank prevented ethanol-induced increases in BDNF in hippocampus and prefrontal cortex (p < 0.05), normalizing levels toward physiological baseline

Significance: Establishes homeostatic BDNF regulation—not simple BDNF augmentation—as integral to Selank’s cognitive-protective action, with relevance for neuroprotective research applications.

5. Selank vs. Semax vs. Diazepam vs. Tuftsin: Comparative Analysis

The following table compares Selank with three closely related or pharmacologically analogous compounds: Semax (the parallel glyproline-extended ACTH fragment developed at IMG RAS), diazepam (the classical benzodiazepine reference standard), and tuftsin (Selank’s parent tetrapeptide). This comparison illuminates both the structural logic of Selank’s design and the pharmacological advantages it carries relative to each comparator.

6. Regulatory Status

6.1 Russian Federation

Selank holds full pharmaceutical approval in the Russian Federation for the treatment of generalized anxiety disorder (GAD), neurasthenia, anxiety and phobic disorders, and cognitive impairment associated with anxiety. Regulatory registration was granted in 2009 following clinical trials conducted at the State Scientific Center for Social and Forensic Psychiatry and affiliated institutions. The compound is manufactured by Peptogen (a spin-off enterprise associated with Lomonosov Moscow State University and IMG RAS) and is available in Russian pharmacies as a 0.15% nasal drop formulation under the brand name CEЛАНК (Selank).

6.2 Commonwealth of Independent States (CIS)

Limited approval exists in several CIS countries, including Ukraine, where Selank is recognized for anxiety disorder treatment and is available in pharmacies. Regulatory status varies across individual CIS member states.

6.3 European Union

Selank is not approved for therapeutic use in the EU. No European Medicines Agency (EMA) marketing authorization application has been submitted. The compound is classified as a research chemical within the EU; its possession and importation for personal research purposes is legally variable by member state and should be evaluated on a country-by-country basis against applicable national laws governing research chemicals and unlicensed medicinal products.

6.4 United States

• FDA Status: Not approved for any therapeutic indication
• DEA Scheduling: Not scheduled; not classified as a controlled substance as of the date of this review
• Compounding: The FDA has taken regulatory action to restrict compounding pharmacies from producing Selank commercially; the regulatory landscape for peptide compounding continues to evolve and should be monitored by researchers
• Current Legal Status: Available as a research chemical for research and laboratory use only, subject to applicable federal and state regulations
• WADA Status: Not specifically listed on the World Anti-Doping Agency Prohibited List as of current available data; researchers and sports scientists should verify current WADA status independently, as classification may change

6.5 Other Jurisdictions

In most non-CIS countries, Selank occupies research chemical status. It is neither prescription-required nor explicitly prohibited in many European and Asian jurisdictions, but carries no regulatory approval for human therapeutic use in any Western market. Researchers outside Russia should confirm the legal status of Selank in their specific jurisdiction prior to procurement or use.

7. Safety Profile

7.1 Preclinical Toxicology

Preclinical safety characterization of Selank was conducted as part of the Russian drug approval process and included acute and chronic toxicity studies, genotoxicity assessment, and reproductive toxicology. The findings were uniformly favorable:

• Acute toxicity: No lethal dose was established at pharmacologically relevant doses; LD50 not reached in rodent models at doses used in pharmacological investigations
• Embryotoxicity: Not observed
• Teratogenicity: Not observed
• Allergenicity: Not demonstrated in standard sensitization models
• Irritancy: No significant local irritation observed
• Drug dependence: Not observed in conditioned-place-preference or self-administration paradigms
• Mutagenicity: Not observed; no genotoxic potential reported in standard battery testing

7.2 Human Clinical Safety Data

Published clinical trials provide the most direct human safety evidence. Across all trials, the absence of benzodiazepine-class adverse events is the defining safety characteristic:

• Zozulya et al. (2008), n=62, 14 days: No significant adverse events in the Selank arm; complete absence of sedation, amnesia, and muscle relaxation; no tolerance or withdrawal upon discontinuation; no drug-drug interactions documented
• Medvedev et al. (2014), n=60: Well-tolerated; no serious adverse events; anxiolytic effect persisted for one week after the last dose without rebound anxiety
• Medvedev et al. (2015), Selank + phenazepam combination: Combination enhanced phenazepam efficacy and reduced phenazepam-associated side effects; no additive adverse event burden attributable to Selank
• Verbenko & Verbenko (2018), n=30, 14-day treatment + 14-day follow-up: No adverse events reported; safety described as acceptable

Mild adverse events reported across all studies and clinical experience include occasional mild nasal irritation or sinus discomfort (intranasal route), rare transient headache, mild injection site reaction (subcutaneous route), rare mild fatigue or dizziness, and occasional sore throat with nasal spray. None of these events were characterized as serious.

7.3 Absence of Benzodiazepine-Class Adverse Events

Selank does not produce any of the following adverse effects that are characteristic of classical benzodiazepines:

• Sedation or hypnosis
• Cognitive impairment or anterograde amnesia
• Psychomotor impairment
• Physical dependence
• Withdrawal syndrome
• Tolerance requiring dose escalation
• Respiratory depression
• Muscle relaxation

The mechanistic basis for this safety advantage is well-characterized: unlike benzodiazepines, which globally enhance GABAergic inhibition across all neuronal populations, Selank’s allosteric modulation is indirect and selective, complemented by simultaneous pro-wakefulness (orexin upregulation) and pro-cognitive (dopaminergic and serotonergic) actions that prevent inhibitory excess. The absence of direct GABA-A receptor agonism means that receptor downregulation, tolerance, and physical dependence—the principal adverse consequences of long-term benzodiazepine use—do not occur.

7.4 Limitations of Current Safety Data

Researchers should note the following important caveats when evaluating the available safety evidence:

1. Trial size: The largest published human trial includes 62 patients. No large-scale (n > 500) randomized controlled trial has been published in international peer-reviewed literature
2. Duration: Most trials span 2–4 weeks. Long-term safety beyond 3 months of continuous use is not formally characterized in the published literature
3. Independent replication: The majority of safety and efficacy data derive from Russian institutions; independent international replication is limited
4. Special populations: Limited published data exist for pediatric, geriatric, pregnant, or renally/hepatically impaired subjects
5. Drug interactions: Systematic pharmacokinetic interaction studies with common drug classes (SSRIs, antidepressants, CNS-active drugs) are largely absent from the published literature

8. Storage & Handling

Proper storage and handling of research-grade Selank are essential to preserve peptide integrity and maintain ≥99.5% purity specifications. The following protocols apply to lyophilized powder (the standard research-grade form) and to reconstituted solutions.

8.1 Lyophilized Powder Storage

8.2 Reconstituted Solution Stability

8.3 Reconstitution Recommendations

• Use sterile water for injection (SWFI) or bacteriostatic water as the reconstitution vehicle
• Standard working concentration: 0.5–1 mg/mL for injectable research use; 1.5 mg/mL for nasal preparations
• Mix by gentle inversion; avoid vigorous vortexing (aggregation risk)
• Prepare single-use aliquots wherever possible to eliminate repeated freeze-thaw cycling
• Inspect for particulates and discoloration before use; discard any solution exhibiting turbidity or precipitation

8.4 Quality Parameters for Research-Grade Material

• HPLC purity: ≥99.5% (main peak, 214 nm) for high-grade research material; minimum acceptable ≥98.0%
• Identity confirmation: Mass spectrometry (ESI-MS), amino acid analysis
• Endotoxin: <1 EU/mg (required for in vivo studies)
• Residual solvents: ICH Q3C compliant; acetate salt form preferred over TFA salt to avoid residual trifluoroacetate contamination

9. Frequently Asked Questions

10. References

All references are verifiable in peer-reviewed literature or official databases. Russian-language journal names are provided in full. PubMed identifiers (PMIDs) and DOIs are included where available.

1. Zozulya AA, Kost NV, Sokolov OYu, et al. “The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity.” Byulleten’ Eksperimental’noi Biologii i Meditsiny (Bulletin of Experimental Biology and Medicine). 2001;131(4):315–317. doi: 10.1023/a:1017979514274. PMID: 11550013. https://pubmed.ncbi.nlm.nih.gov/11550013/
2. Zozulia AA, Neznamov GG, Siuniakov TS, Kost NV, Gabaeva MV, Sokolov OIu, et al. “[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia].” Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova. 2008;108(4):38–48. [In Russian]. PMID: 18454096. https://pubmed.ncbi.nlm.nih.gov/18454096/
3. Uchakina ON, Uchakin PN, Miasoedov NF, Andreeva LA, Shcherbenko VE, Mezentseva MV, et al. “[Immunomodulatory effects of selank in patients with anxiety-asthenic disorders].” Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova. 2008;108(5):71–75. [In Russian]. PMID: 18577961. https://pubmed.ncbi.nlm.nih.gov/18577961/
4. Ershov FI, Uchakin PN, Uchakina ON, Mezentseva MV, Alekseeva LA, Miasoedov NF. “[Antiviral activity of immunomodulator Selank in experimental influenza infection].” Voprosy Virusologii (Problems of Virology). 2009;54(5):19–24. [In Russian]. PMID: 19882898. https://pubmed.ncbi.nlm.nih.gov/19882898/
5. Volkova A, Shadrina M, Kolomin T, Andreeva L, Limborska S, Myasoedov N, Slominsky P. “Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission.” Frontiers in Pharmacology. 2016;7:31. doi: 10.3389/fphar.2016.00031. PMID: 26924987. PMC: PMC4757669. https://pmc.ncbi.nlm.nih.gov/articles/PMC4757669/
6. Alieva AK, Kasian A, Filatova EV, Rybalkina EYu, Pavlova GV, Andreeva LA, Shadrina MI, Myasoedov NF, Slominsky PA, Limborska SA, Kolomin TA. “GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells.” Frontiers in Pharmacology. 2017;8:89. doi: 10.3389/fphar.2017.00089. PMC: PMC5328971. https://pmc.ncbi.nlm.nih.gov/articles/PMC5328971/
7. Kasian A, Kolomin T, Andreeva L, Bondarenko E, Myasoedov N, Slominsky P, Shadrina M. “Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats.” Behavioural Neurology. 2017;2017:5091027. doi: 10.1155/2017/5091027. PMC: PMC5322660. https://pmc.ncbi.nlm.nih.gov/articles/PMC5322660/
8. Medvedev VE, Tereshchenko ON, Israelian AYu, et al. “[A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders].” Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova. 2014;114(7):17–22. [In Russian]. PMID: 25176261. https://pubmed.ncbi.nlm.nih.gov/25176261/
9. Medvedev VE, Tereshchenko ON, Kost NV, et al. “[Optimization of the treatment of anxiety disorders with selank].” Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova. 2015;115(6):33–40. [In Russian].
10. Kolik LG, Nadorova AV, Antipova TA, Kruglov SV, Kudrin VS, Durnev AD. “Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats.” Byulleten’ Eksperimental’noi Biologii i Meditsiny. 2019;167(5):641–644. doi: 10.1007/s10517-019-04588-9. PMID: 31625062. https://pubmed.ncbi.nlm.nih.gov/31625062/
11. Kozlovskii II, Danchev ND. “The optimizing action of the synthetic peptide Selank on a conditioned active avoidance reflex in rats.” Neuroscience and Behavioral Physiology. 2003;33(7):639–643. doi: 10.1023/A:1024444321191.
12. Kozlovskaya MM, Kozlovskii II, Val’dman EA, Seredenin SB. “Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress.” Neuroscience and Behavioral Physiology. 2003;33(9):853–860. doi: 10.1023/A:1025988519919.
13. Inozemtseva LS, Karpenko EA, Dolotov OV, Levitskaya NG, Kamensky AA, Andreeva LA, Myasoedov NF. “Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo.” Doklady Biochemistry and Biophysics. 2008;421(1):241–243.
14. Kolomin T, Shadrina M, Slominsky P, Limborska S, Myasoedov N. “A New Generation of Drugs: Synthetic Peptides Based on Natural Regulatory Peptides.” Neuroscience & Medicine. 2013;4(4):223–252. doi: 10.4236/nm.2013.44035. https://www.scirp.org/journal/paperinformation?paperid=40560
15. Semenova TP, Kozlovskaya MM, Tiushnyakova VN, Kozlovskii II. “[Use of Selank to correct measures of integrative brain activity and biogenic amine levels in adult rats resulting from antenatal hypoxia].” Eksperimental’naya i Klinicheskaya Farmakologiya (Experimental and Clinical Pharmacology). 2007. [In Russian].
16. Verbenko G, Verbenko V. “The effectiveness of selank in the treatment of adjustment disorder.” Psychosomatic Medicine and General Practice. 2018;3(1). doi: 10.26766/pmgp.v3i1.86. https://e-medjournal.com/index.php/psp/article/download/86/233
17. Kost N, Sokolov O, Zozulya SA, Myasoedov NF. “Combined Action of Benzodiazepine Tranquilizers and Peptide Anxiolytic Selank in BALB/c Mice.” Neurochemical Journal. 2025. doi: 10.1134/S1819712425700783. https://link.springer.com/10.1134/S1819712425700783
18. PubChem. “Selank—CID 11765600.” National Library of Medicine, National Institutes of Health. Accessed March 2026. https://pubchem.ncbi.nlm.nih.gov/compound/Selank
19. Ashmarin IP. “Regulatory peptides in brain functions and the design of novel peptide drugs.” Zhurnal Vysshei Nervnoi Deyatel’nosti im. I.P. Pavlova. 2007. (As cited in Volkova et al., 2016)
20. V’yunova TV, Andreeva LA, Grigorenko AP, Myasoedov NF. “Allosteric modulation of GABA-A receptor by Selank.” Doklady Biochemistry and Biophysics. 2014. (As cited in Volkova et al., 2016 and Alieva et al., 2017)